Introduction
T-cell acute lymphoblastic leukemia (T-ALL) remains a clinical challenge due to the high rate of relapse driven by multidrug resistance (MDR). While the role of altered glycosylation in cancer is well-documented, the specific regulatory mechanisms linking non-coding RNAs to surface glycan changes have been poorly understood. This study identifies a novel regulatory circuit—the ZFAS1/miR-150/ST6GAL1 axis—that modulates the sialylation of the Epidermal Growth Factor Receptor (EGFR), thereby activating pro-survival signaling pathways in resistant leukemia cells.
Glycan Profiling and the Role of ST6GAL1
To understand the biochemical basis of resistance, researchers compared drug-sensitive (CR) and adriamycin-resistant (CR/A) T-ALL cell lines using MALDI-TOF mass spectrometry. The analysis revealed significant differences in $N$-glycan composition, specifically an upregulation of sialylated glycoforms in the resistant cells.
Among the enzymes responsible for these changes, the sialyltransferase ST6GAL1 emerged as a critical player. Experimental knockdown of ST6GAL1 was found to restore drug sensitivity and increase apoptosis in resistant cells, while its overexpression conferred resistance to sensitive cells.
The ZFAS1/miR-150/ST6GAL1 Regulatory Axis
The study mapped a complex "competing endogenous RNA" (ceRNA) network. The long non-coding RNA (lncRNA) ZFAS1 acts as a molecular "sponge" for miR-150. Under normal conditions, miR-150 suppresses the expression of ST6GAL1. However, in MDR T-ALL cells, elevated levels of ZFAS1 sequester miR-150, effectively upregulating ST6GAL1.
This increase in ST6GAL1 leads to enhanced $\alpha$2,6-sialylation of EGFR. This modification stabilizes the receptor and triggers the PI3K/Akt pathway, a major survival cascade that allows cancer cells to bypass the lethal effects of chemotherapy.
Clinical Validation and Patient Outcomes
The relevance of this axis was confirmed in clinical samples from 46 T-ALL patients. ST6GAL1 expression was significantly higher in patients with multidrug resistance compared to those without.
Importantly, patients with high ST6GAL1 expression exhibited significantly poorer overall survival ($P = 0.0249$), highlighting the enzyme's potential as both a prognostic biomarker and a therapeutic target.
Conclusion
This research provides a comprehensive map of how non-coding RNAs regulate the "sugar coating" of cancer cells to drive drug resistance. By targeting the ZFAS1/miR-150/ST6GAL1 axis or the downstream PI3K/Akt pathway, clinicians may eventually be able to overcome multidrug resistance in T-ALL patients. Future work will focus on identifying the upstream triggers for ZFAS1 and developing effective delivery systems for RNA-based therapies.
Summary updated